The contribution of community pharmacy to improving the public’s health: summary report of the literature review 1990–2007 by Anderson, Claire et al.
The conTribuTion of communiTy pharmacy To improving The public’s healTh: 
summary reporT of The liTeraTure review 
1990–2007
The conTribuTion of communiTy pharmacy To improving The public’s healTh: evidence from The peer-reviewed liTeraTure 2001-20042 The conTribuTion of communiTy pharmacy To improving The public’s healTh: evidence from The peer-reviewed liTeraTure 2001-2004 3
managemenT summary
 conTenTs
1.0 Introduction.........................................................4
2.0 Methods  .............................................................4
3.0 Results ................................................................7
3.1 Smoking cessation ..............................................7 
3.2 Cardiovascular disease prevention  ....................8
3.3 Diabetes  .............................................................9
3.4 Hypertension .....................................................10
3.5 Weight management .........................................11
3.6 Contraception and sexual health  .....................11
3.7 Folic acid and pregnancy ..................................13
3.8 Substance misuse  ............................................13
3.9 Osteoporosis risk assessment/prevention   .......13
3.10 Immunisation   ................................................14
3.11 Oral health ......................................................14
4.0 Discussion ........................................................15
4.1 Effectiveness of interventions  ..........................15 
4.2 Delivering public health services   ....................17
4.3 Future research   ...............................................19
5.0 Conclusions.......................................................20
References  ....................................................... 21-29
Claire Anderson
Professor of Social Pharmacy
Division of Social Research in Medicines and Health
School of Pharmacy,
University of Nottingham. 
Alison Blenkinsopp 
Professor of the Practice of Pharmacy, 
Department of Medicines Management, 
Keele University.
Miriam Armstrong 
Chief Executive, 
PharmacyHealthLink.
pharmacyhealThlink 2009
The conTribuTion of communiTy pharmacy            
To improving The public’s healTh:                        
summary reporT of The liTeraTure review  
1990–2007
lisT of Tables and figures
Table 1: Evidence categorisation used 
in the review 
Table 2: Numbers of papers and topic 
areas included in the review
Table 3: Countries of origin of studies 
included in the review – 2004–2007
Table 4: Countries of origin of studies 
included in the review – 2001–2004
Table 5: Countries of origin of studies 
included in the review – 1990–2001
figure 1: Evidence summary of where 
community pharmacy can contribute to 
improving the public’s health 
The conTribuTion of communiTy pharmacy To improving The public’s healTh: summary reporT of The liTeraTure review 1990–20074 The conTribuTion of communiTy pharmacy To improving The public’s healTh: summary reporT of The liTeraTure review 1990–2007 5
1.0 inTroducTion
This report presents a summary of findings from a review of 
evidence published in peer-reviewed journals between 1990 and 
2007 on the contribution of community pharmacy to improving 
the public’s health. This document brings together the evidence 
identified from a series of literature reviews covering the periods 
1990–2001, 2001–2004 and 2004–2007.1 This summary focuses 
on evidence of effectiveness, quality, costs/cost-effectiveness 
and skill mix of potential relevance and application to community 
pharmacy in the UK. 
2.0 meThods
A systematic search of international peer-reviewed literature was 
undertaken covering the period 1 January 1990 to 31 October 2007. 
The aim was to review, summarise and evaluate the evidence 
relating to the contribution of community pharmacy to improving the 
public’s health both in the UK and internationally. The scope of the 
review is described in detail elsewhere (Anderson et al. 2001) and 
studies included related to:
•	 promoting	health	and	wellbeing	(eg	nutrition,	physical	activity);
•	 	preventing	illness	(eg	smoking	cessation,	immunisation,	travel	
health);
•	 identifying	ill	health	(eg	screening	and	case	finding);
•	 	the	maintenance	of	health	for	those	with	chronic	or	potentially	
long-term conditions (e.g. diabetes, asthma, hypertension).
The search strategy and search terms are listed in detail elsewhere 
(Anderson	et	al.	2001;	Anderson	et	al.	2005).	All	searches	included	
non-English language literature. Studies with English abstracts were 
assessed for inclusion on the basis of the abstract. Hand searches 
were made of the Health Education Journal, Pharmaceutical Journal, 
International Journal of Pharmacy Practice, Journal of Social and 
Administrative Pharmacy, Pharmacy World and Science, Annals of 
Pharmacotherapy, British Pharmaceutical Conference abstracts. 
The quality criteria and data extraction frameworks used are 
described in detail elsewhere (Anderson et al. 2001). Briefly, the 
review used two approaches to assess the quality of evidence: 
(1) The Health Development Agency’s Evidence Base 2000 for 
standards of transparency, systematicity and relevance (Health 
Development	Agency	2000);	and	(2)	the	evidence	categorization	
used by the Department of Health in its National Service 
Frameworks (NSFs) (Department of Health 2001) and shown in 
Table 1.
Table 1. evidence caTegorisaTion used in 
The review
a1 Systematic reviews which include at least one randomised 
controlled trial (RCT) e.g. Cochrane reviews
a2 Other systematic and high quality reviews which 
synthesise references
b1 Individual RCTs
b2 Individual non-randomised experimental/intervention 
studies
b3 Individual well-designed non-experimental studies, 
controlled statistically if appropriate. Includes studies 
using case control, longitudinal cohort, matched pairs or 
cross-sectional random sample methodologies, plus well-
designed qualitative studies and well-designed analytical 
studies including secondary analysis
c1 Descriptive and other research and evaluation not in B 
(e.g. convenience samples)
c2 Case studies and examples of good practice
d Summary review articles and discussions of relevant 
literature and conference proceedings not otherwise 
classified
All abstracts were reviewed by AB and CA and papers ordered for 
the studies to be included in the review. Data were extracted using 
a structured matrix, with a sample of reviews cross-checked to 
assure accuracy. 
In total 196 papers were reviewed (see Table 2) and the extracted 
data were compiled into three matrices to show the country of 
origin (see Tables 3-5) for each review period. 
The focus of this report is the future development of community 
pharmacy in the UK. The narrative therefore concentrates on 
studies of relevance and potential applicability to the UK. A full list 
of references is included at the end of this document.2   
Table 2. numbers of papers and Topic areas included in The reviews3 
Topic 1990-2001 2001-4 2004-7 Totals
smoking cessaTion 7 9 20 36
cvd prevenTion 14 5 15 34
diabeTes 3 - 12 15
hyperTension - 2 3 5
weighT managemenT 1 1 5 7
conTracepTion (including ehc) 4 20 13 37
sexual healTh - 6 6 12
folic acid in pregnancy 2 4 - 6
subsTance misuse 8 - 8 16
osTeoporosis prevenTion - 5 8 13
immunisaTion 5 - 2 7
oral healTh 3 - - 3
skin cancer 3 - - 3
asThma 1 - - 1
head lice 1 - - 1
ToTal 52 52 92 196
Table 3. counTries of origin of sTudies included in The reviews: 2004–2007
Topic uk europe us canada australia & new 
Zealand
other Total
smoking cessaTion 2 2 5 4 3 4 20
cvd prevenTion 2 3 10 15
diabeTes 1 3 3 2 3 12
hyperTension 2 1 3
weighT managemenT 5 5
conTracepTion (including ehc) 6 2 4 1 13
sexual healTh 2 1 2 1 6
subsTance misuse 6 2 8
osTeoporosis prevenTion 6 1 1 8
immunisaTion 1 1 2
ToTal 20 8 31 17 9 7 92
1Anderson, C, Blenkinsopp, A, Armstrong, M (2003). The contribution of community pharmacy to improving the public’s health: Evidence from the peer-reviewed literature of 1990–2001. London, 
PharmacyHealthLink and Royal Pharmaceutical Society of Great Britain. www.phlink.org.uk/ (Accessed 16/3/08).
Anderson, C, Blenkinsopp, A, Armstrong, M (2003). The contribution of community pharmacy to improving the public’s health: Evidence from the UK non peer-reviewed literature of 1990–2002. 
London, PharmacyHealthLink and Royal Pharmaceutical Society of Great Britain. www.phlink.org.uk/ (Accessed 16/3/08).
Armstrong M, Lewis R, Blenkinsopp A, Anderson C (2005). The contribution of community pharmacy to improving the public’s health: An overview of the evidence-base from 1990-2002 and 
recommendations for action. London, PharmacyHealthLink and Royal Pharmaceutical Society of Great Britain. www.phlink.org.uk/ (Accessed 16/3/08.)
Anderson C, Blenkinsopp A, Armstrong  M (2005). The contribution of community pharmacy to improving the public’s health: evidence from the peer-reviewed literature 2001-2004. London , 
PharmacyHealthLink. www.phlink.org.uk/ (Accessed 16/3/08.) 
Anderson C, Blenkinsopp A, Armstrong M (2008). The contribution of community pharmacy to improving the public’s health. Literature review update 2004–2007. London, Pharmacy HealthLink. 
www.phlink.org.uk/ (Accessed 16/3/08.)
2Studies are only cited in this summary when their findings are particularly relevant to this report.  The previous PharmacyHealthLink reviews, or the original research articles, should be consulted 
for a more detailed review of the literature.
3The matrices exclude papers on factors influencing community pharmacy involvement in public health activities.
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Table 4. counTries of origin of sTudies included in The reviews: 2001–2004
Topic uk europe us canada australia & new 
Zealand
other Total
smoking cessaTion 3 5 1 9
cvd prevenTion 3 1 1 5
diabeTes -
hyperTension 1 1 2
weighT managemenT 1 1
conTracepTion (including ehc) 8 2 6 3 1 20
sexual healTh 4 1 1 6
folic acid in pregnancy 1 2 1 4
subsTance misuse -
osTeoporosis prevenTion 1 3 1 5
immunisaTion -
ToTal 20 6 17 5 3 1 52
Table 5. counTries of origin of sTudies included in The reviews: 1990–2001
Topic uk europe us canada australia & new 
Zealand
other Total
smoking cessaTion 4 2 1 7
cvd prevenTion 6 5 1 1 1 14
diabeTes 1 2 3
hyperTension -
weighT managemenT 1 1
conTracepTion (including ehc) 3 1 4
sexual healTh -
folic acid in pregnancy 1 1 2
subsTance misuse 6 2 8
osTeoporosis prevenTion -
immunisaTion 1 4 5
oral healTh 2 1 3
skin cancer prevenTion 1 1 1 3
asThma 1 1
head lice 1 1
ToTal 25 8 14 2 1 2 52
3.0 resulTs 
3.1 smoking cessaTion
Thirty-six papers were reviewed. 
Overview of the evidence: 
•		Community	pharmacist	trained	in	behaviour-change	methods	
are effective in helping clients stop smoking (B1). 
•		Community	pharmacy-based	stop	smoking	services	are	cost-
effective (B1).
•		Abstinence	rates	from	one-to-one	treatment	services	provided	
by community pharmacists and primary care nurses are similar. 
Rates are lower for specialist one-to-one advice than group 
interventions with specialist behavioural support. (B3).
•		Training	increases	knowledge,	self-confidence	and	positive	
attitude of pharmacists and their staff in relation to smoking 
cessation (B1).
•		Involving	pharmacy	support	staff	may	increase	the	provision	
of brief advice and recording of smoking status in patient 
medication records (B3).
Community pharmacy-based stop smoking services, run by trained 
pharmacy staff are effective and cost-effective. Abstinence rates 
at one year in two UK RCTs of community pharmacy-based stop 
smoking services were 14.3% (Maguire et al. 2001) and 12% 
(Sinclair et al. 1998). A large UK study using a quasi-experimental 
design with 1500 participants and validated abstinence found 
similar abstinence rates at four weeks (19%) for people receiving 
the service on a one-to-one basis from community pharmacists 
and primary care nurses, compared with 30% for those receiving a 
group treatment service from ‘behaviour change experts’ (McEwen 
et al. 2006).  The authors commented that the difference may be 
due to the additional behavioural support given by the latter.  
There is some evidence of effectiveness of the involvement of 
pharmacists in smoking cessation in hospital pharmacy and prison 
settings, and of the feasibility of using a computer programme as 
the basis for a community pharmacy-based smoking cessation 
service. A pharmacist-led smoking cessation service initiated 
from a hospital pharmacy and continued at outpatient visits, or 
in a community pharmacy, was assessed using a randomised 
controlled trial design (Vial et al. 2002). The 12-month abstinence 
rates were 38% in the hospital group and 24% in the community 
group. A computer-based service (Pro-Change) was tested in a 
community pharmacy setting with the aims of improving local 
access to services and to engage low income and unemployed 
smokers in quit attempts (Anderson & Mair 2002). Access was 
improved compared with a general practice-based service, and 
programme users included a large proportion of people on low 
incomes or without work. 
A US study tested the feasibility of a protocol to target specific 
people for questioning and giving ‘brief interventions’ (akin to 
giving ‘brief advice’ in the UK) about smoking in two community 
pharmacies (Purcell et al. 2006). The smoking status of 57% and 
29% of eligible people was recorded in the two pharmacies.
3.1.1 Quality
Quality criteria developed in two studies could be used further to 
develop frameworks for UK services.
A quality criteria assessment framework developed in a Scottish 
study included 13 elements: cessation rates of 30% (one 
month);	28%	(three	months);	14.3%	(one	year);	and	in	those	not	
abstaining,	to	achieve	a	reduction	in	smoking	levels;	improve	
access	to	smoking	cessation	services;	client	groups	from	areas	
of	inequality;	client	satisfied	with	the	service;	successful	use	of	
the	‘stages	of	change’	model;	ensure	ongoing	written	material	
is	available;	subjective	estimate	of	reduced	workload	in	general	
practice;	avoid	increasing	time	pressure	on	pharmacists;	
pharmacists	satisfied	with	service;	achieve	a	cost	of	£300	per	
quitter (Cramp et al. 2007). Six of the 13 criteria were achieved: 
improved	access;	clients	satisfied	with	service;	successful	use	
of	‘stages	of	change’	model;	one	month	30%	success	rate;	three	
months	28%	success	rate;	and,	in	those	not	abstaining,	achieve	a	
reduction in smoking levels.
A quality framework for advice during sales of over-the-counter 
nicotine replacement therapy (NRT) developed in Norway had 12 
criteria (six relating to customer service and six on content of 
pharmaceutical advice) (Granas et al. 2004). A mystery shopper 
study found a mean score of 17.3 (of a possible 45) on a first visit 
and 16.2 on the second visit, highlighting there were areas for 
improvement.
3.1.2 Costs and Cost-effeCtiveness
The	cost	per	quitter	was	£525	in	a	Scottish	study,	compared	with	
the	quality	criterion	of	£300	in	that	programme	(Cramp	et	al.	
2007).	In	other	studies	costs	were	£300	or	£83	per	life-year	saved	
(Sinclair et al. 1999) and cost per life-year saved ranged from 
£197	to	£351	for	men	and	£181	to	£722	for	women	(Crealey	et	al.	
1998). A study modelling cost-effectiveness of a US community 
pharmacy-based service (Tran et al. 2002) found that, depending 
on the smoker’s age at the time of cessation, the incremental 
discounted cost-effectiveness was US$720–1418 per life-year 
saved (the equivalent cost was US$290–1155 in the Crealey study 
based on the 1997 exchange rate).
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3.1.3 skill mix and training
Training, especially in behaviour change methods, was found to 
be essential to the success of pharmacy stop smoking services. 
Without training pharmacists are more likely just to respond to 
smokers’ requests for advice rather than to proactively initiate 
conversations about smoking (Sinclair et al. 1998).
In a US study, the pharmacy which involved its dispensing 
technicians in implementing a protocol for offering brief 
interventions (brief advice in the UK) and recording smoking 
status, had recording rates and numbers of interventions roughly 
double those in the pharmacy that did not use technicians (Purcell 
et al. 2006).
There is potential benefit to be gained from a whole staff approach 
in community pharmacy, although there are no comparative data 
for when pharmacists alone have provided the service.
3.1.4 attitudes and praCtiCe
There is consistent evidence across the review period that 
pharmacists are apprehensive about proactively raising smoking 
with their customers but that after training, pharmacists’ practice 
becomes more proactive.
Two surveys of US community pharmacists provided further 
confirmatory evidence of the tendency among most pharmacists 
to adopt a reactive approach towards smoking cessation (Kotecki 
&	Hillery	2002;	Aquilino	et	al.	2003).	When	asked	whether	it	
was important to know if a patient smoked, the vast majority of 
pharmacists agreed that it was. However, only one in ten had any 
systematic method of obtaining this information and recording 
it in a way that made it easily accessible when the patient next 
presented a prescription.
One study from Canada (Brewster et al. 2005) and another from 
Australia (Edward et al. 2006) explored pharmacists’ attitudes, 
and a further study from the US (Purcell et al. 2006) investigated 
actual practice in relation to unsolicited questioning and advice 
about smoking. Most pharmacists did not routinely ask about or 
record the smoking status of their customers. Pharmacists in the 
Canadian and Australian studies were apprehensive about raising 
the topic of smoking cessation and expressed some concerns about 
alienating their customers. 
 
3.2 cardiovascular disease prevenTion 
Thirty-four papers were reviewed. 
Overview of the evidence:
•		Pharmacy	services	are	effective	in	reducing	lipid	levels	and	
cardiovascular risk scores and the effect can be sustained one 
year after the intervention ended (B1).
•		Evidence	from	an	RCT	of	effectiveness	of	a	pharmacy	service	
resulted in significantly increased prescribing of anti-platelet 
medicines, lipid-lowering treatment, and smoking cessation 
treatments (B1).
•		Using	pharmacy	medication	records	to	identify	clients	at	‘high	
risk’ of coronary heart disease (CHD) is effective and can be 
used for instigating health promotion measures (B1).
•		A	workplace	based	cardiovascular	risk	reduction	programme	
provided by community pharmacists significantly reduced blood 
pressure and improved lipid profiles but had no effect on weight 
(B2).
•		A	community	pharmacy-based	service	where	peer	health	
educators measured blood pressure and completed 
cardiovascular risk profiles for people with hypertension was well 
received by patients and GPs (B2).
•		There	is	insufficient	evidence	to	determine	whether	or	not	
‘screening’ activities (e.g. blood pressure measurement) carried 
out in community pharmacies are an effective use of resources 
(B3). 
3.2.1 effeCtiveness
A series of Canadian studies have investigated the effectiveness 
of community pharmacy-based intervention in CVD risk-factor 
reduction focused on lipid management. An RCT tested the effects 
of community pharmacist intervention on lipid management in 
‘high	risk’	CVD	patients	(Tsuyuki	et	al.	1999,	2002;	Simpson	et	
al. 2001). The primary endpoint was a composite measure of a 
complete fasting cholesterol profile, addition of lipid-regulating 
medication or modification of previous lipid-regulating medication. 
Secondary outcomes were patient satisfaction and quality of life. 
Community pharmacists in 44 pharmacies held a consultation 
with patients identified as ‘high risk’ during which a cholesterol 
test was conducted, information was provided on risk factors 
and recommendations were made to the patient’s doctor about 
medication changes. The external data committee recommended 
early study termination due to benefit, the primary endpoint being 
reached in 58% of intervention patients compared with controls 
(P<0.001).
The second Canadian Study of Cardiovascular Risk Intervention 
by Pharmacists (SCRIP Plus) trial was a ‘before and after’ study 
of the effects of pharmacist intervention in lipid management 
(Yamada et al. 2005). Forty-two pharmacies recruited 419 patients 
to the study. The mean reduction in LDL level was 0.5 mmol/L from 
a baseline mean of 3.5 mmol/L, representing a 13.4% reduction in 
relative risk, and 27% of patients reached their target LDL level. 
One year after completion of SCRIP Plus, patients were followed up 
and their LDL cholesterol measured. The mean LDL level was not 
significantly different from that one year earlier showing that the 
improvement was sustained. Nevertheless, most patients still had 
not reached their target LDL level. 
The Canadian Pharmacist Intervention in Risk Reduction (PIRR) 
trial used a ‘before-after’ design (Semchuk et al. 2007). Forty-one 
pharmacies recruited 217 patients. The primary outcome was the 
proportion of patients with changes in targeted medication. There 
was a significant increase in the prescribing of anti-platelet and 
lipid-lowering treatments and of smoking cessation treatments. 
This trial was ended early due to under-recruitment.
An RCT was conducted in a single community pharmacy with 51 
patients (Nola et al. 2000). Patients were those already taking 
medication for hypertension and/or diabetes and were identified 
through the pharmacy computerised patient medication records 
(PMRs). Patients attended a ‘screening day’ where a nurse took 
blood samples that were tested off-site. The pharmacist advised 
on diet, exercise and medication. Risk factor profiles improved in 
the intervention but not in the control group, with 32% of patients 
in the former and 15% in the latter achieving target cholesterol 
levels.
A workplace-based cardiovascular risk reduction programme 
provided by community pharmacists led to significant reductions 
in systolic and diastolic blood pressure readings, and in LDL, but 
had no significant effect on weight loss (John et al. 2006). Fifty-six 
workers with risk factors for cardiovascular disease took part, of 
mean age 41 years. Thirty-seven had diabetes mellitus and 19 did 
not. The number of pharmacist visits per participant ranged from 
one to thirteen, with a mean value of seven. 
In the Cardiovascular Health Awareness Programme (CHAP) in 
Canada, people aged over 65 years with hypertension were invited 
by their doctor to attend a session in their local pharmacy with 
a trained volunteer peer health educator (PHE) (Chambers et al. 
2005). The PHE measured their blood pressure and completed a 
cardiovascular risk profile. A copy of the findings was given to 
the pharmacist and faxed to the doctor. Feedback from doctors, 
PHEs and pharmacists was positive and the pharmacists reported 
increased patient traffic and more dialogue with patients. An RCT 
of CHAP was recently completed and the findings are due to be 
published.4
Two audits of aspirin purchases in UK community pharmacies in 
1996 and 1998 showed that 33% and 27% of patients respectively 
appeared to be taking prophylactic aspirin without their GP’s 
knowledge (Horne 1998). Interviews with 128 patients purchasing 
low-dose aspirin or taking it on prescription found that community 
pharmacists were viewed as a highly acceptable source of 
information about aspirin and heart disease (Black et al. 1998). 
Just over half of the patients viewed the community pharmacy 
as a suitable venue to obtain information about aspirin, with the 
remainder expressing some concern about privacy.
3.2.2 Costs 
The costs of providing a community pharmacy-based risk 
reduction service were calculated (Simpson et al. 2001). The 
10-year Framingham risk decreased in the intervention group by 
5.2% (from 17.3% to 16.4%) during the four-month study period.  
The costs to the pharmacy for providing the service were $22 
(Canadian dollars) per patient and the costs to healthcare funders 
were $6.40. 
3.2.3 aCCeptability to the publiC
In two small UK studies, a single community pharmacy worked 
in collaboration with local GPs. In one study, GP records were 
used to identify people who were likely to be ‘at risk’ and were 
invited to have an assessment in the pharmacy (Joubert & Choo 
2003). This appears to be the first programme to have targeted 
people in collaboration with, and thus with the support of, local 
doctors. Roughly half of the people assessed were found to need 
referral back to the GP and the remainder received lifestyle advice. 
In around half of those assessed, changes in medication were 
recommended and implemented or initiation of new treatment was 
recommended and started. Unfortunately no data were reported on 
outcomes of the lifestyle advice provided. Another study in a single 
community pharmacy used risk assessment software with referral 
to the GP where needed (David et al. 2003). For those clients 
advised by the pharmacist there was a significant improvement 
in risk score at three months but this was not sustained at six 
months.    
3.3 diabeTes
Fifteen studies, including two reviews, were included.
Overview of the evidence:
•		There	is	evidence	of	effectiveness	of	diabetes	management	
services provided from pharmacies, leading to a significantly 
greater reduction of approximately 1% in HbA1c compared with 
0.3% in controls (A1).
•		Evidence	from	an	RCT	that	pharmacy-based	targeting	of	people	
with risk factors for diabetes, incorporating ‘point of care’ blood 
4Jones et al. (2008): paper published after the review period, but systolic blood pressure in the intervention group showed statistically and clinically significant sustained improvement.
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glucose testing prior to referral, was more effective and more 
cost-effective than targeting and referral alone (B1).
•		A	diabetes	screening	and	cardiovascular	risk	assessment	service	
resulted in new diagnoses for 16% of those referred, and therapy 
changes in 42% (B2).
•		Community	pharmacy-based	diabetes	monitoring	and	
information-giving shows promise in improving diabetic control, 
but further research is needed (B2).
•		Pharmacy-based	group	education	for	people	with	diabetes	shows	
promise but more evidence is needed (B3).
3.3.1 effeCtiveness
A systematic review (Machado et al. 2007a) with meta-analysis 
of data from 2247 patients in 16 studies found a significant 
reduction in HbA1c levels in the pharmacists’ intervention group 
(1.00	±	0.28%;	P	<	0.001)	but	not	in	controls	(0.28	±	0.29%;	P	=	
0.335). 
Subsequent to this systematic review, an Australian study was 
published that tested the effectiveness of a community pharmacy-
based	diabetes	service	in	controlled	trials	(Krass	et	al.	2007a);	
149 patients received the intervention at 28 pharmacies. The trial 
showed statistically and clinically significant reductions in HbA1c 
of 0.97% (compared with 0.27% in controls). 
Pharmacy-based screening for undiagnosed diabetes was the 
subject	of	three	studies	(Australia,	the	US	and	Switzerland).	
The US study included diabetes testing together with CVD 
risk assessment (Snella et al. 2006). The Australian and US 
studies used simple risk factor assessment as a filter prior to 
diabetes screening and involved testing of 1286 and 888 people 
respectively	(Snella	et	al.	2006;	Krass	et	al.	2007b).	The	Swiss	
paper reported findings from a national screening campaign in 
which 93,258 people were tested (Hersberger et al. 2006). Follow-
up to identify subsequent diagnoses was conducted only in the 
Australian study, where 1.7% of those tested were diagnosed as 
having diabetes.  In the US study 81% of those screened were 
referred, 15% of whom had blood glucose measurements outside 
the defined range. In the Swiss campaign 6.9% of those tested 
were categorised as ‘possible diabetes’.
A community pharmacy-based group education model for people 
with diabetes was tested in a Swedish study (Sarkadi & Rosenqvist 
1999). HbA1c levels among 39 patients who had participated in 
eight educational groups for at least five months were significantly 
lower at six but not at 12 months.
3.3.2 Costs and Cost-effeCtiveness
A cost-effectiveness analysis was done for 99 patients who had 
received the pharmacy-based diabetes service in the earlier of the 
two Australian trials (Taylor et al. 2005). Pharmacists were paid 
$40	(Australian	dollars,	approximately	£18)	per	hour.	The	mean	
cost of the intervention over nine months was $383 (Australian 
dollars,	approximately	£175)	per	patient.
The cost-effectiveness of pharmacy-based risk assessment plus 
blood glucose testing (‘sequential screening’, SS) in generating 
a diagnosis of diabetes was compared with pharmacy-based risk 
assessment with referral to the GP for blood glucose testing in an 
Australian study (Krass et al. 2007b). The rates of diagnosis were 
1.7% and 0.2% respectively. The SS method resulted in fewer 
referrals to the GP, a higher uptake of referrals and was more cost-
effective.
3.4 hyperTension
Five studies, including one systematic review, were included.
Overview of the evidence:
•		A	systematic	review	with	meta	analysis	of	13	RCTs	covering	
2246 patients found significant reductions in systolic, but not 
diastolic, blood pressure (A1).
•		Simply	measuring	blood	pressure	in	the	pharmacy	may	in	itself	
have an effect on blood pressure control without additional 
intervention (B1).
A systematic review included 13 trials and found evidence of 
effectiveness of pharmacist input in significantly reducing systolic 
blood pressure (Machado et al. 2007b).
A randomised controlled trial in one community pharmacy tested 
an intervention comprising an individualised plan for action 
in relation to diet, physical activity, obesity and alcohol intake 
(Garcao & Cabrita 2002). Blood pressure control improved 
significantly in the intervention group. It is difficult to assess 
the impact of the non-drug aspect of the intervention as the 
pharmacists also identified and made recommendations about 
drug-related problems. A controlled study showed that blood 
pressure control improved in the intervention arm of a community 
pharmacy-based ‘health promotion programme’ (Cote et al. 2003). 
Computer software was used to flag study patients and prompt 
pharmacists to intervene. So few interventions were recorded by 
the pharmacists that the researchers hypothesised that simply 
measuring blood pressure in the pharmacy may have an effect on 
control.  
A single community pharmacy offered free blood pressure 
testing to people aged 30–64 years with the pharmacist inviting 
individuals to take part (Hampton et al. 1990). The 70 clients 
were given a copy of their results to take to their doctor. The GP 
records of 40 clients were subsequently checked and the pharmacy 
blood pressure reading was recorded in 10 clients. GP attitudes 
were explored in interviews, where the response was noted by 
the authors to be ‘not enthusiastic’. The authors concluded that 
pharmacist measurement of blood pressure and referral to a 
GP was unlikely to be accepted unless part of a co-ordinated 
programme.
3.5 weighT managemenT
Seven studies were reviewed.
Overview of the evidence:
•		Community	pharmacy-based	weight	reduction	programmes	
appear to show promise but further evidence is needed (B3).
Two of three intervention studies showed a positive effect while the 
third showed no significant change in weight.  
A service provided in a single pharmacy in the US resulted in 
a mean weight loss of 3.6 kg among 216 people over a mean 
duration of 26 weeks (Lloyd et al. 2007). One in three people were 
able to decrease their BMI category, and one in four decreased 
their CVD risk status. Blood pressure in those with uncontrolled 
hypertension at baseline was more likely to be controlled. The 
service involved an initial consultation with the pharmacist 
(scheduled for 1.5 hours) followed by 15-minute fortnightly follow-
ups until target weight was reached, and then a three-monthly 
follow-up. The service was provided free during the study period 
and is now offered on a fee-paying basis. 
In a Swiss study, 3800 people who had participated in a 
community pharmacy-based diabetes screening, were invited to 
take part in a programme of lifestyle counselling. Of the 1370 
who took part, the mean weight lost was between 0.6 and 1.9 kg 
at three months. People in the high-risk counselling group (245) 
showed weight loss of 2.25% at three months and 2.74% at one 
year (Botomino et al. 2007). 
In addition to the specific studies on weight management, weight 
reduction was one of several outcome measures in a workplace 
health-improvement programme where community pharmacists 
provided education about cardiovascular disease, identification 
of drug therapy problems, and the importance of routine blood 
pressure, pulse and weight measurements (John et al. 2006). No 
significant effect on weight was found.
One study showed that a community pharmacy-based weight loss 
programme had successful outcomes at three months (Ahrens et 
al. 2003). In a Danish study 19 community pharmacies provided 
‘slimming courses’ attended by 269 clients (Tubro 1999). Average 
weight loss (self-reported by clients measured on scales in 
the pharmacy) was 5.3 kg for females and 6.2 kg for males. At 
one-year follow-up 20% of clients who completed the course had 
maintained a weight loss of 5 kg or more.
3.6 conTracepTion and sexual healTh
3.6.1 ContraCeption
Thirty-seven studies were included, two of which were structured 
reviews.  
Overview of the evidence:
•		Emergency	hormonal	contraception	(EHC)	can	be	effectively	and	
appropriately supplied by pharmacists (B3).
•		Pharmacy	supply	of	EHC	enables	most	women	to	receive	it	within	
24 hours of unprotected intercourse (B3).
•		Community	pharmacies	are	highly	rated	by	women	as	a	source	of	
supply and associated advice for EHC on prescription, by Patient 
Group Directions (PGDs), or over-the-counter (OTC) sales (B3).
•		A	small	minority	(10%)	of	women,	choose	pharmacy	supply	of	
EHC in order to maintain anonymity (B3).
•		Pharmacists	were	positive	about	their	experience	of	providing	
emergency hormonal contraception through PGDs and over-the-
counter sales (B3).
•		The	role	of	pharmacy	support	staff	in	provision	of	EHC	services	
is reported by pharmacists to be important, but there are no data 
available to enable assessment of their contribution (B3).
During the period of the review there were legal changes and 
developments in NHS service provision that enabled the supply 
of EHC through UK community pharmacies without prescription. 
Latterly the community pharmacy contractual framework 
(introduced in England in 2005) led to a large increase in the 
proportion of pharmacies with a consultation area. 
Pharmacy supply of EHC enables most women to receive it within 
24 hours of unprotected sexual intercourse and are highly rated 
by women. One UK study, following the deregulation of EHC, has 
shown a subsequent decrease in requests for EHC in Accident and 
Emergency departments (Kerins et al. 2004).  Training has been 
shown to improve pharmacists’ performance in supply of EHC 
in accordance with protocols  (Bacon et al. 2003) and mystery 
shopping has indicated that pharmacists supply is according 
to protocols in the majority of cases (Anderson et al. 2001). 
Pharmacists are very satisfied with delivering EHC services and 
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view them as a way to improve their role in patient-focused care 
(Bissell et al. 2006). Some pharmacists have concerns about the 
potential for repeated use of EHC, and the possible effect of easier 
access to EHC, on the incidence of sexually transmitted infections 
(STIs) (Bissell et al. 2001). 
Making EHC available OTC did not change the level of use, but 
did change where women obtained it from, with more women 
using pharmacies as the source (Marston et al. 2005). A large 
US trial of advance availability of EHC found no increase in risky 
sexual behaviour and no significant reduction in the number of 
pregnancies (Rocca et al. 2007). No differences were observed 
in use of regular contraception or in risky sexual behaviour by 
women obtaining EHC from pharmacies (Raine et al. 2005), and 
aadolescents aged younger than 16 years behaved no differently 
in response to increased access to EHC from other age groups 
(Harper et al. 2005). 
Pharmacy services were in general highly rated by women. There 
were some concerns about confidentiality and privacy among a 
substantial minority of users, particularly among younger women 
(Anderson et al. 2005).  In general, the way in which services 
are configured affects their use, with women preferring services 
that give them privacy whilst treating them in a sympathetic 
and non-judgmental manner.  It is worth noting that many of 
the studies were conducted prior to the increase in availability 
of consultation areas in pharmacies. Some concerns were also 
reported by service users about the appropriateness of additional 
and unsolicited information and advice from pharmacists about 
future contraceptive use and STIs.
Repeat depot contraceptive injections were provided by 26 
pharmacies in the US with pharmacists trained in injection 
technique (Maderas & Landau. 2007). Established depot users 
were offered the choice of having their injection at a pharmacy 
rather than at their usual clinic. The service was found to be 
feasible and acceptable to the public.
The majority of community pharmacists in a US survey reported 
dispensing prescriptions for contraception for adolescents, but 
over half felt inadequately trained in dealing with adolescent-
specific issues. The authors concluded that most pharmacists are 
inadequately trained in this respect and younger adolescents, in 
particular, may face more barriers to care than older adolescents. 
3.6.2 sexually transmitted infeCtions (stis)
Twelve studies were reviewed.
Overview of the evidence: 
•		Public	interest	in	the	availability	of	advice	on	contraception	and	
safe sex through pharmacies is high (B3).
•		Quality	and	confidentiality	were	identified	by	service	users	as	
important considerations in selecting a pharmacy for advice on 
women’s health (B3).
•		Pharmacists	express	support	for	involvement	in	promoting	safer	
sex and contraception, but are rarely asked for such advice, and 
are reluctant to offer it (B3).
•		Pharmacists	generally	have	positive	attitudes	towards	
involvement in prevention of transmission of infection (B3).
•		Community	pharmacy-based	Chlamydia	testing	and	treatment	
services increase client access (C1).
Two	UK	surveys	(Ralph	et	al.	2001;	Watson	et	al.	2003)	examined	
pharmacists’ attitudes to providing sexual health services and one 
US survey looked at pharmacy services for adolescents. Watson 
et al. (2003) surveyed 99 of the128 pharmacists in Grampian, 
Scotland and found that as part of their services to drug users, 
nearly all stocked condoms. Fifty-seven stated that they stocked 
extra-strong condoms and two stocked dental dams. Lack of 
training, time pressures and a lack of private consultation areas 
were the major barriers to service provision in this survey. Most 
pharmacies stocked relevant leaflets, but fewer than half had a list 
of agencies dealing with sexual health problems.  
Two	papers	(McAllister	et	al.	2002;	Mackie	et	al.	2002)	evaluated	
the acceptability and accessibility of a sexual health service for 
young people in a city centre pharmacy in Glasgow. Users of the 
service were either satisfied, or very satisfied with it, and the 
timing and location of the service were the most commonly quoted 
reasons for attendance. 
Two pilot studies, one from the UK (Baraitser et al. 2007) and one 
from the Netherlands (Van Bergen et al. 2004), demonstrated the 
feasibility of providing Chlamydia screening through community 
pharmacies. The authors of the UK study conclude that the 
provision of Chlamydia testing in community pharmacy seemed to 
increase access to testing among those who would not otherwise 
have been tested, and could potentially reduce demand in other 
sexual health services, and that community pharmacies are a 
suitable location for Chlamydia testing and treatment. Clients 
valued speed and convenience in the service and a friendly, non-
judgmental approach. Further work is required to encourage uptake 
by young men and in improving confidentiality at the pharmacy 
counter. The Dutch study also found a pharmacy-based Chlamydia 
testing service to be feasible and acceptable to service users.
3.7 folic acid and pregnancy
Six studies were reviewed.
Overview of the evidence: 
Pharmacy staff are positive about promoting the role of folic acid 
in pregnancy, but there is no published evidence of the effects of 
interventions on behaviour (B3).
Pharmacy staff are positive about promoting the role of folic 
acid in pregnancy but are likely to perceive it as a sensitive topic 
(Rajyaguru & Anderson 1999).  A study exploring the attitudes 
of pharmacy staff to discussing folic acid use with customers 
during an information campaign, showed that staff were more 
likely to raise the subject with their regular customers (Anderson & 
Rajyaguru 2002). 
One in three Dutch pharmacists reported using an additional label 
about folic acid when they dispensed oral contraceptives (De Jong-
Van den Berg et al. 1999). Influencing factors included perceptions 
of the attitudes of medical practitioners and pharmacists’ own 
concerns about ‘imposing’ unsolicited information on women.
An action research study showed that using a core team in 
participating pharmacies, and sharing feedback from staff and 
customers from a folic acid education campaign, resulted in 
refinement and development of the pharmacy-based activities 
(Meijer et al. 2003). Feedback from women who received 
information labels plus leaflets about folic acid when their 
contraceptive pill was dispensed showed that very few responded 
negatively. 
3.8 subsTance misuse
Sixteen studies were reviewed.
Overview of the evidence:
•		Most	drug	users	value	community	pharmacy-based	services	
highly (B3).
•		Community	pharmacy-based	supervised	methadone	
administration services can achieve high attendance rates and 
be acceptable to clients (B3).
•		Positive	attitudes	among	pharmacists	are	correlated	with	higher	
service provision for drug users (B3).
•		Pharmacy-based	needle-exchange	schemes	can	achieve	high	
rates of returned injecting equipment and are cost-effective 
(B3).
Several studies were surveys tracking the service provision of 
needle exchange and methadone-supervised administration in 
pharmacies in England and Scotland.  Substantial increases in 
provision over time were found (see for example, Britton et al. 
2006;	Matheson	et	al.	2007).
For pharmacists not involved in service provision for drug 
misusers, the key barriers were concerns about the effects on 
other customers, safety, workload and remuneration (Matheson 
& Bond 1999). There is some evidence from a qualitative study 
that pharmacy customers may hold more positive attitudes about 
services for drug misusers than pharmacists expect (Lawrie et al. 
2004). The authors of this study concluded that their participants 
seemed to have a clearer understanding of the need for needle 
exchange services than for methadone maintenance treatment and 
that the public wanted methadone administration to be supervised 
in a private area.
A study of needle exchange services in three settings found that 
pharmacy services were used more frequently and had a higher 
percentage of returned injecting equipment (Cameron et al. 2004).
3.9 osTeoporosis risk assessmenT/prevenTion
Thirteen studies were reviewed, covering community pharmacy-
based osteoporosis screening, a risk management service for 
patients taking long term oral corticosteroids and a falls preven-
tion service. 
Overview of the evidence:
•		Community	pharmacy-based	services	for	osteoporosis	risk	
assessment were well received, and identified women at 
different levels of risk (C1).
•		Not	all	studies	conducted	follow-up	after	the	assessment,	
but those that did found that preventive treatments had been 
initiated and that women reported having made lifestyle 
changes (C1).
Several studies described the uptake of services including 
assessments of osteoporosis risk and bone density measurement 
with advice and referral. Services were offered free of charge. 
Overall the results show that community pharmacy-based bone 
health assessments can identify people who need to be referred 
for	further	medical	assessment	(Elliott	et	al.	2002a,	2002b;	Lata	
et	al.	2002;	Lai	et	al.	2003;	Cerulli	&	Zeolla	2004).	There	is	some	
evidence that advice given to women identified to be at lower risk 
may result in increased dietary intake of calcium and increased 
exercise. User feedback about the services was highly positive 
(Gray	et	al.	2002;	Cerulli	&	Zeolla	2004).	A	cost-effectiveness	
evaluation found that offering such a service could be financially 
viable	depending	on	the	local	situation	(Cerulli	&	Zeolla	2004).	The	
transferability of this finding from the US to the UK is unclear.
One study tested the feasibility of referral for screening by 
local family doctors using a list of criteria to target women who 
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might be ‘at risk’ (MacLaughlin et al. 2005). The service was 
well received by women in all of the studies. Where follow-up 
was conducted, a substantial proportion of women had new 
prescriptions for relevant medicines, and substantial percentages 
of women reported having made lifestyle changes (MacLaughlin et 
al.	2005;	Summers	&	Brock	2005;	Naunton	et	al.	2006).
A small RCT of a community pharmacy service tested the effect 
of pharmacist-led risk management activities in patients 
taking long-term oral corticosteroids (McDonough et al. 2005). 
Intervention pharmacies provided an educational pamphlet on 
osteoporosis prevention and reviewed patients’ medication while 
controls provided usual care. Ninety-six patients participated and 
those in the intervention group were significantly more likely to be 
taking calcium supplements after nine months. 
3.10 immunisaTion
Seven studies were reviewed.
Overview of the evidence:
•		Immunisation	services	can	be	provided	safely	through	
community pharmacy (B3).
•		Pharmacy	patient	medication	records	are	effective	in	identifying	
and flagging ‘at risk’ clients to be invited for immunisation and 
can increase the percentage of the target group immunised (B3).
•		User	satisfaction	with	pharmacy-based	immunisation	services	
is high (C1).
•		Support	for	non-physician	delivered	immunisation	is	greater	for	
adult than for child immunisation (C1).
Immunisation services can be provided safely through community 
pharmacies	(Weitzel	&	Goode	2000).	Pharmacy	patient	medication	
records are effective in identifying ‘at risk’ clients who can then 
be invited for immunisation (Davidse & Perenboom 1995) and 
pharmacy-based	services	can	extend	the	reach	of	immunization	
programmes (Davidse & Perenboom 2005).  User satisfaction with 
this service is high and support for non-physician immunisation 
was found to be greater for adult than for child immunisation 
(Grabenstein	2001;	Ernst	et	al.	2001).	A	UK	pharmacy-based	
immunisation	service	(for	influenza	in	particular)	seems	to	have	
been reasonably well-accepted by patients, physicians and 
pharmacists (Hind et al. 2004).
3.11 oral healTh
Three studies were reviewed, two of which were from the UK. The 
most recent was published in 1999 and there is very little evidence 
on the contribution of community pharmacy to improving oral 
health. Most pharmacists say they believe sugar-free medicines 
are important for children, but they perceive opportunities 
for recommending them as limited, since most requests from 
customers are for named medicines (McVeigh et al. 1999). In 
this survey one-quarter of pharmacists reported having received 
formal training about oral health, which was found to increase the 
likelihood and effectiveness of pharmacists giving advice.
4.0    discussion
This review included 196 studies published over an 18-year period and provides substantial evidence of the positive contribution 
community pharmacists can make to improving the public’s health. The diagram below represents pictorially the strength of published 
evidence of where community pharmacy has been shown to contribute. 
evidence summary of where communiTy pharmacy can conTribuTe To improving  
The public’s healTh
***	Good	evidence	for;	**Some	evidence	for;	*Some interesting evidence but further research is needed.
4.1 effecTiveness of inTervenTions
The strongest evidence of effectiveness is for smoking cessation, lipid management, diabetes, emergency contraception, flu 
immunisation and drug misuse. 
4.1.1 smoking Cessation
UK studies have demonstrated that community pharmacy has a clear role in providing cost-effective smoking cessation services with 
comparable outcomes to other one-to-one services provided in primary care, however, more intensive group support services have higher 
quit	rates	(McEwen	et	al.	2006;	Bauld	et	al.	2009;	Boyd	&	Briggs	2009).	Both	pharmacists	and	pharmacy	support	staff,	with	appropriate	
training, can provide effective smoking cessation support. There is some evidence from UK and US studies that although pharmacists 
view smoking cessation advice as an important activity, they are not as proactive in their practice as they might be. 
Diabetes***
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Cardiovascular disease prevention & management**
Hypertension**
Lipid management***
Weight Management*
Smoking Cessation***
Drug misuse***
Sexual Health*
Emergency Contraception***
Folic Acid Promotion*
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Falls prevention*
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4.1.2 CardiovasCular disease (Cvd) 
prevention 
lipid managemenT 
Evidence of effectiveness of community pharmacy input into CVD 
prevention is strongest for the management of lipid levels, where 
a series of RCTs has demonstrated improvement that can be 
sustained for at least one year beyond the initial intervention.
cardiovascular risk facTor assessmenT
Studies of risk factor assessment for heart disease show that 
members of the public will take up such services where they are 
offered free of charge.  Research findings mainly describe the 
profile of risk factors found and the numbers of clients referred for 
medical assessment, with few data on outcomes of information 
and advice-giving by pharmacy staff.  The economics of case-
finding and risk assessment services in pharmacies in the UK 
remain unclear. A national Vascular Risk Assessment programme 
began in England in 2009 and pharmacies are a potential provider 
(Anonymous 2008c). Although overall there appear to be positive 
outcomes associated with pharmacy-based CVD risk factor 
assessment services, the studies conducted do not so far provide 
sufficient evidence to make a clear assessment. Most studies have 
only measured outcomes in the short term so the extent to which 
any changes are sustained cannot be quantified. 
4.1.3 diabetes
There is evidence from Australian studies of effectiveness of 
pharmacy-based diabetes management services that they lead 
to a significantly greater reduction in HbA1c compared with 
controls. An Australian RCT (Krass et al. 2007b) also showed that 
pharmacy-based targeting of people with risk factors for diabetes 
together with ‘point of care’ blood glucose testing prior to referral 
was more effective and cost-effective than targeting and referral 
alone. 
4.1.4 hypertension
Community pharmacy-based hypertension management has 
potential. A systematic review (Machado et al. 2007b) reported 
improvements in control in trials of community pharmacy-based 
hypertension management. Some studies (for example, Garcao 
& Cabrita 2002) explicitly included non-drug approaches within 
the pharmacist’s care plans. Disappointingly however, no studies 
reported on clients’ uptake of this advice and as a result the 
contribution that non-drug approaches make to an improvement in 
blood pressure control cannot be quantified. 
4.1.5 Weight management
Currently the evidence for weight management might best be 
summed up as ‘promising and in need of further study’. In the 
meantime, there are opportunities to collect data on effectiveness 
and it is encouraging to note that a government-funded Australian 
study will evaluate a community pharmacy weight management 
service which itself is based on a critical review of the literature 
and the development of an evidence-based service model (Rieck et 
al. 2006). A recent literature review of eleven primary care studies 
of nursing interventions to support weight management concluded 
that ‘at best, perhaps 10% of patients entering a nurse-led 
support programme may achieve a clinically significant weight 
loss’ (Brown & Psarou 2008). 
 
4.1.6 ContraCeption and sexual health
The first NHS community pharmacy service for the initiation and 
supply of combined oral contraception and progesterone-only 
contraception was introduced in 2008 (Anonymous 2008b).  
Further research is needed to evaluate these emerging models of 
possible future sexual health services in community pharmacies in 
the UK.  
There is a clear role, however, for pharmacists in the sale and 
supply of emergency hormonal contraception (EHC) and women are 
happy with the services provided. The extent to which pharmacists 
provide associated advice about STIs and future contraception to 
women obtaining EHC is less clear. 
 
Research in sexual health has emanated from a wide range of 
countries and the role of the community pharmacist in sexual 
health is developing worldwide. Pilot studies have shown that 
community pharmacies can provide Chlamydia screening and 
treatment services including epidemiological partner treatment. 
The	antimicrobial	azithromycin	is	now	available	as	a	non-
prescription medicine in the UK for the treatment of Chlamydia 
where a test has demonstrated the presence of infection 
(Anonymous 2008a). 
 
There is evidence of a desire by the public for easy access 
to information on both contraception and safer sex and that 
they would be willing to receive this advice from pharmacists.  
Pharmacists themselves appear to want an expanded advisory 
role in sexual health. Access to training that incorporates and 
encourages networking with other local service providers is likely 
to be crucial in increasing pharmacists’ confidence in dealing with 
these issues appropriately and effectively. 
4.1.7 substanCe misuse
Community pharmacy-based needle-exchange schemes are 
cost-effective, and supervised methadone administration services 
achieve high attendance rates and are acceptable to clients. All 
these services appear to be reasonably well-accepted by clients, 
pharmacists and the public. Research conducted prior to the 
introduction of the new pharmacy contractual framework in 2005 
identified a preference for more private facilities for methadone 
supervision, but no published research has yet evaluated the 
effects of the increased percentage of pharmacies with a 
consultation area on user feedback.
Community pharmacy plays an important role in harm reduction 
and these services are highly valued by users. Positive pharmacist 
attitudes are correlated with higher service provision for users.  
There is potential for more advice on preventing the transmission 
of infections (e.g. STIs/ blood borne viruses) to be given by 
pharmacists to drug service users.
4.1.8 osteoporosis risk assessment and 
prevention
Community pharmacy-based osteoporosis prevention services are 
generally based around bone mineral density measurement, often 
used with structured questionnaires to assess other risk factors 
and provide the basis for individualised advice or referral to the 
GP. The studies provide evidence that this approach is positively 
received by service users and patients who need referral are 
identified. Doctors in the UK expressed mainly positive views about 
the service provided. 
Only one study reported on the outcomes of advice given by 
pharmacy staff to clients who did not need to be referred. The 
findings showed that knowledge about bone health increased 
and there was evidence that daily calcium intake was increased. 
Several US studies assessed women’s willingness to pay for 
osteoporosis risk assessment but the transferability of the findings 
to the UK is questionable.  
 
4.1.9 flu immunization
Extensive evidence from the US shows that community pharmacies 
can	safely	provide	influenza	immunisation.	UK	studies	have	
shown that pharmacy patient medication records are an effective 
method of targeting specific patient groups to remind them about 
immunisation.
 
4.2 delivering public healTh services
From the studies reviewed, the following factors were shown 
to have an influence on the effectiveness of public health 
interventions in a community pharmacy-based setting.
 
4.2.1 serviCe Quality
Two service quality frameworks for smoking cessation were 
identified. No other studies assessed service quality.
User feedback is critical in understanding acceptability and 
quality of community pharmacy services and the scope for 
service improvement. However in the UK, it is only in emergency 
contraception supply that there has been a sustained research 
effort to obtain user perspectives. 
4.2.2 Costs and Cost-effeCtiveness
Three studies provide evidence that community pharmacies can 
provide cost-effective smoking cessation services. Two robust cost-
effectiveness analyses of a diabetes management service and a 
comparison of two methods of diabetes screening were identified.  
More recent studies were more likely to target specific groups 
of people for both screening and intervention, which is likely to 
increase cost-effectiveness.
There was no obvious theoretical basis, nor justification, for 
the ‘dose’ of pharmacist input used in the studies we reviewed 
and hence cost-effectiveness of different ‘doses’ is impossible 
to determine. Monthly face-to-face consultations were common 
and there was no discussion in the papers about whether there 
might be a ‘dose response curve’ which could help to identify 
optimal input. Some recent studies have used telephone follow-
ups as an alternative option to face-to-face consultations. One 
trial also included the possibility of follow-up using electronic 
communication but this was not used in practice.
4.2.3 skill mix and training
Few studies included or discussed the contribution of pharmacy 
staff other than the pharmacist. One study involved pharmacy 
technicians identifying people to receive brief advice on smoking. 
This was successful in doubling the numbers identified and 
recording their smoking status compared to the control pharmacy 
which did not involve their technicians. Another study reported 
pharmacy support staff conveying information on folic acid to 
minority ethnic groups in their own languages. 
  
Several intervention studies included training for the participating 
pharmacists and provided further evidence of the effectiveness of 
training in supporting role development and changing practice. 
Training and education can also link pharmacists more closely 
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with primary care staff and local services, thus reducing their 
concerns about how pharmacy public health initiatives might be 
received by pharmacy users and other healthcare professionals.
 
Studies from the early 1990s showed that most pharmacists felt 
that their education at undergraduate and pre-registration level 
had not prepared them adequately for involvement in public health 
activities, although a recent Masters study indicated that recently 
qualified pharmacists feel more prepared for such roles than was 
the case in the past (Nicholson S, personal communication).  Given 
the importance of training and education in delivering public 
health initiatives, research is urgently needed to determine current 
perceptions of recently qualified pharmacists on the training and 
education they received as undergraduates, and how this has 
supported their subsequent practice. 
Multidisciplinary public health ‘core competencies’ for specialists 
and practitioners have been developed for all public health 
professionals based around the Faculty of Public Health’s 10 key 
areas for public health practice5. These competencies provide a 
common framework, but in the longer term, consideration may 
need to be given to the development of standardised training for 
pharmacists and their staff who wish to provide public health 
services, but do not wish to follow a public health career path. 
For example, the Health Protection Agency has drafted a core 
curriculum and national minimum standards for immunisation 
training and is considering the inclusion of pharmacists under 
these standards.
 
4.2.4 publiC attitudes and preferenCes
A recent Department of Health market research survey (Department 
of  Health 2008) found that few members of the public currently 
report using health-related services offered by some pharmacies 
(other than regular monitoring of current health conditions and 
health screening for conditions such as diabetes and cholesterol) 
but that many were interested in doing so.   The greatest users 
of community pharmacies for general health advice were women, 
respondents with young children and those in lower socio-
economic groups.  
 
According to this user profile, pharmacy could play a greater role 
in helping to tackle health inequalities, however, the published 
studies add little to our understanding of the effectiveness of 
community pharmacies in engaging ‘hard to reach’ higher-risk 
clients in assessments of their health. Therefore the issue of 
whether services should be ‘open access’ and available on a 
walk-in basis to all (often argued to be the strength of community 
pharmacy setting) versus a more targeted approach, remains 
unresolved. 
 
A survey conducted by the Patients Association (2008) found 
that almost half of the respondents said they would be ‘very 
happy’ to use a pharmacy for initial screening or diagnostics, 
while 25% said they would prefer the GP and 19% a nurse. The 
figures relating to regular monitoring tests show slightly higher 
acceptance of pharmacy provision with 55% happy to use a 
pharmacy, 19% preferring the GP and 21% a nurse. Almost 
60% agreed that ‘pharmacists should be allowed and should 
receive resources to provide a much broader range of community 
healthcare advice and services’, indicating broad support for a 
wider public health role for community pharmacy, with a quarter 
disagreeing. However, respondents also had some concerns about 
privacy and confidentiality with only one in three agreeing that 
their local pharmacist ‘always paid attention’ to these aspects. 
Respondents also expressed concern about whether the amount 
of space in their local pharmacy was sufficient to allow privacy. 
Unfortunately the survey did not explore whether the respondent’s 
pharmacy had a consultation area and, if so, whether they had 
experience of using it.
 
The survey conclusions also raised some areas of concern to be 
addressed. Patients were willing to seek a wider range of services, 
such as screening, from pharmacies but with the proviso ‘if seen 
to be integrated with GP services’. The authors also concluded that 
‘Patients’ concerns about confidentiality, privacy and expertise 
may be discouraging fuller use of pharmacy services’. The authors 
make several recommendations to the profession including:
 
•		invest	in	privacy	and	confidentiality	so	that	patients	feel	able	to	
ask	for	advice,	and	access	services;
•		establish	a	confidentiality	charter	covering	consultation	rooms,	
over-the-counter	services,	inter-staff	discussion	of	patients;
•		work	constructively	with	other	primary	care	professionals	to	
provide a safe, seamless service for their patients.
4.3 fuTure research
Despite the considerable interest recently shown by UK Governments in further developing the public health role of pharmacy6, the lack 
of growth of recent UK studies in many key areas of the review (with the possible exceptions of emergency hormonal contraception and 
substance misuse) is a matter for concern. In contrast Canada has generated a substantial body of community pharmacy-based research 
since the 2004 literature review update, and Australia has continued to expand its existing substantial evidence base (see Box for more 
information). 
ouTpuTs of a naTional sTraTegy for pharmacy research in ausTralia
In Australia a strategic long-term programme of pharmacy practice research has produced a substantial evidence base 
to underpin proposed new community pharmacy services funded by the government. The key was collaborative working 
between the Australian government, the contract negotiators (The Pharmacy Guild of Australia), Schools of Pharmacy and 
the professional body. The Community Pharmacy Agreement Research and Development Programme  helped to establish 
Australia as an international leader in evidence based community pharmacy services. Research and development was one 
of the priorities identified in the Fourth Agreement between the government and The Pharmacy Guild of Australia (2005–10). 
Funding of up to $19 million (8.9 million GBP) has been allocated for the Research and Development Programme to identify 
research and development priority areas in community pharmacy service provision and then to fund projects with the 
greatest potential to deliver services with positive health outcomes for consumers and economic impacts for the health 
system. 
An example of how research from the programme has directly influenced the planning and implementation of new services 
is the research on diabetes that led implementation of the pilot Diabetes Medication Assistance Service  from 2007. Since 
September 2007, eligible patients with type 2 diabetes are able to schedule in-pharmacy appointments (with pharmacists 
in participating pharmacies) to receive assistance in managing their diabetes medicines, using a glucometer and self-
monitoring their blood glucose. Pharmacists are also involved in the patient’s lifestyle management by providing regular 
blood pressure and weight measurements, as well as general health and lifestyle advice. To participate in the pilot 
programme, pharmacists must be credentialed against a competency based training course. Pharmacies must also have a 
private area within the pharmacy to allow for confidential sit-down consultations with the patient. 
Given the central place of pharmacy as part of a network of health service providers within the local community, the profession needs 
to work with other stakeholders to obtain resources to support a robust programme of targeted research.  In particular there is an 
urgent need for further research on collaboration between community pharmacies and GP practices to determine how best to agree and 
implement a service plan for individual patients, and follow-up the outcomes.  Further research is also required to investigate the use of 
community pharmacies by members of lower socio-economic groups and other disadvantaged groups. The findings of this review can be 
used to support this process.
5  See www.publichealthregister.org.uk/ for more details.
6 Department of Health (2008).  White paper. Pharmacy in England: Building on strengths – delivering the future. Department of Health: London.  
http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_083815 
Department of Health (2005). Choosing health through pharmacy: A programme for pharmaceutical public health 2005-2015.  Department of Health: London.  
http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/Browsable/DH_4107796 
Department of Health (2003) A Vision for Pharmacy in the New NHS. Department of Health: London. www.doh.gov.uk/pharmacyvision/visionforpharmacy.pdf
Department of Health (2000) Pharmacy in the Future – Implementing the NHS Plan. Department of Health: London. www.doh.gov.uk/pharmacyfuture
NHS Scotland (2002) Pharmacy for Health: The Way Forward for Pharmaceutical Public Health in Scotland. Public Health Institute of Scotland: Glasgow. www.phis.org.uk
Government of the National Assembly for Wales (2001) Plan for Wales 2001. Government of the National Assembly for Wales. www.planforwales.wales.gov.uk
Department of Health, Social Services and Public Policy (2003) Making it Better: A Strategy for Pharmacy in the Community. Department of Health, Social Services and Public Policy: Belfast.  
www.dhsspsni.gov.uk/publications/2003/makingitbetter.pdf 
Department of Health, Social Services and Public Policy (2002) Investing for Health. Department of Health, Social Services and Public Policy: Belfast. www.investingforhealthni.gov.uk
7 www.guild.org.au/ (Accessed 11/3/08).
8 www.guild.org.au/uploadedfiles/Research_and_Development_Grants_Program/News_and_Events/RDmarketingbooklet.pdf  (Accessed 11/3/08).
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5.0 conclusions
The evidence of effectiveness of community pharmacy public 
health interventions is strongest in smoking cessation, diabetes, 
EHC, flu immunisation and drug misuse. 
Evidence in the detection and management of cardiovascular risk 
factors was mixed, with convincing evidence in hypertension and 
lipid management, but less so in risk factor assessment where 
data on outcomes are sparse. Many studies in key topic areas 
were conducted in settings that vary from those in the UK and 
therefore further research is required to test the transferability 
of their findings to a UK context. Some evidence of effectiveness 
was found relating to osteoporosis risk management and weight 
management. These areas remain promising and should be tested 
in pilot studies and further research.
A more systematic approach needs to be taken to the development 
of the public health contribution of community pharmacy if the 
full potential of this role is to be realised.  The evidence shows 
that making training available to all pharmacy staff, particularly 
in identifying individuals ‘at risk’ and for behavioural support 
techniques, is key if effective interventions are to be delivered.  
The relative influence of drug and non-drug approaches on patient 
outcomes (especially health inequalities), data recording and links 
to the wider health infrastructure should be included as part of 
the evaluation of future studies, so that a greater understanding 
of the unique characteristics of pharmacy-based public health 
interventions is acquired.
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